ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

PHVS Pharvaris NV

22,60
-0,93 (-3,95%)
03 Mai 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Pharvaris NV PHVS NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
-0,93 -3,95% 22,60 18:34:21
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
23,77 22,475 23,90 22,60 23,53
mais cotações »

Notícias Recentes

Data Hora Fonte Título
10/04/202417:10GLOBEPharvaris Reports Fourth Quarter and Full Year 2023..
10/04/202417:08GLOBEPharvaris Appoints David Nassif, J.D., as Chief Financial..
04/04/202407:50GLOBEPharvaris to Present Deucrictibant Clinical Data at the CIIC..
18/03/202407:50GLOBEPharvaris Announces Phase 3 Clinical Study Design for..
06/03/202408:50GLOBEPharvaris to Present Deucrictibant Clinical Data at Upcoming..
05/03/202408:50GLOBEPharvaris to Participate in the Leerink Global Biopharma..
22/02/202408:50GLOBEPositive Results from CHAPTER-1 Phase 2 Study of..
16/02/202408:50GLOBEPharvaris Announces Extraordinary Meeting of Shareholders
26/01/202408:50GLOBEPharvaris to Present at the WSAAI Annual Meeting 2024
22/01/202409:35DJNPharvaris Says FDA Lifted Clinical Hold on Application for..
22/01/202408:50GLOBEPharvaris Announces FDA Lifting of the Clinical Hold of..
05/01/202408:50GLOBEPharvaris Provides Business Update and Outlines 2024..
08/12/202320:00GLOBEPharvaris Presents Deucrictibant Clinical Data and Analysis..
06/12/202309:02GLOBEPharvaris Announces Pricing of $300 Million Underwritten..
06/12/202308:50GLOBEPharvaris Announces Positive Top-line Phase 2 Data from the..
30/11/202308:50GLOBEPharvaris to Present at the GA²LEN UCARE Conference 2023
15/11/202308:50GLOBEPharvaris Appoints Stefan Abele, Ph.D., as Chief Technical..
09/11/202313:00GLOBEPharvaris Presents Deucrictibant Clinical Data and..
02/11/202307:50GLOBEPharvaris Reports Third Quarter 2023 Financial Results and..
30/10/202307:50GLOBEPharvaris To Present at the ACAAI 2023 Annual Scientific..
13/10/202307:50GLOBEPharvaris To Present at the APAAACI 2023 International..
04/10/202308:34GLOBEPharvaris To Present at the CIIC Fall 2023 Conference
19/09/202307:50GLOBEPharvaris To Participate in the 2023 Cantor Global..
06/09/202307:51GLOBEPharvaris To Present at the 18th German Allergy Congress
06/09/202307:50GLOBEPharvaris To Participate in the Morgan Stanley 21st Annual..
23/08/202307:50GLOBEPharvaris To Present at the 2023 HAEi Regional Conference..
07/08/202307:50GLOBEPharvaris Reports Second Quarter 2023 Financial Results and..
21/07/202311:20GLOBEPharvaris Presents Clinical Data at the 2023 U.S. HAEA..
26/06/202308:39DJNPharvaris: FDA Removes Clinical Hold of Deucrictibant for..
26/06/202307:50GLOBEPharvaris Announces FDA Removal of Clinical Hold of..
20/06/202307:50GLOBEPharvaris Announces $70 Million Private Placement Financing
10/06/202319:01GLOBEData of Deucrictibant for the On-Demand Treatment of HAE..
01/06/202307:50GLOBEPharvaris Announces Annual Meeting of Shareholders
08/05/202307:50GLOBEPharvaris Reports First Quarter 2023 Financial Results and..
06/05/202314:00GLOBEDeucrictibant Data Highlighted in Multiple Presentations at..

Seu Histórico Recente

Delayed Upgrade Clock